YM-900

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 526938

CAS#: 143151-35-3

Description: YM-900, also known as YM-90K, is an AMPA receptor antagonist and glutamate receptor antagonist potentially for the treatment of stroke.

Chemical Structure

img
YM-900
CAS# 143151-35-3
Instruction

Theoretical Analysis

MedKoo Cat#: 526938
Name: YM-900
CAS#: 143151-35-3
Chemical Formula: C11H7N5O4
Exact Mass: 273.05
Molecular Weight: 273.208
Elemental Analysis: C, 48.36; H, 2.58; N, 25.63; O, 23.42

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: YM-90K; YM-900; YM90K; YM900; YM 90K; YM 900.

IUPAC/Chemical Name: 6-(1H-imidazol-1-yl)-7-nitro-1,4-dihydroquinoxaline-2,3-dione

InChi Key: GBWIZNYOJITVFI-UHFFFAOYSA-N

InChi Code: InChI=1S/C11H7N5O4/c17-10-11(18)14-7-4-9(16(19)20)8(3-6(7)13-10)15-2-1-12-5-15/h1-5H,(H,13,17)(H,14,18)

SMILES Code: O=C1NC2=C(C=C(N3C=CN=C3)C([N+]([O-])=O)=C2)NC1=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 273.21 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Hashimoto T, Narikawa S, Huang XL, Minematsu T, Usui T, Kamimura H, Endou H. Characterization of the renal tubular transport of zonampanel, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist, by human organic anion transporters. Drug Metab Dispos. 2004 Oct;32(10):1096-102. PubMed PMID: 15377641.

2: Iwasaki K, Chung EH, Egashira N, Hatip-Al-Khatib I, Mishima K, Egawa T, Irie K, Fujiwara M. Non-NMDA mechanism in the inhibition of cellular apoptosis and memory impairment induced by repeated ischemia in rats. Brain Res. 2004 Jan 2;995(1):131-9. PubMed PMID: 14644478.

3: Katsuta K, Umemura K, Ueyama N, Matsuoka N. Pharmacological evidence for a correlation between hippocampal CA1 cell damage and hyperlocomotion following global cerebral ischemia in gerbils. Eur J Pharmacol. 2003 Apr 25;467(1-3):103-9. PubMed PMID: 12706462.

4: Nakano M, Ueda H, Li JY, Matsumoto M, Yanagihara T. A potent AMPA/kainate receptor antagonist, YM90K, attenuates the loss of N-acetylaspartate in the hippocampal CA1 area after transient unilateral forebrain ischemia in gerbils. Life Sci. 2001 Sep 14;69(17):1983-90. PubMed PMID: 11589513.

5: Turski L, Schneider HH, Neuhaus R, McDonald F, Jones GH, Löfberg B, Schweinfurth H, Huth A, Krüger M, Ottow E. Phosphonate quinoxalinedione AMPA antagonists. Restor Neurol Neurosci. 2000;17(1):45-59. PubMed PMID: 11490077.

6: Stutzmann JM, Bohme GA, Boireau A, Damour D, Debono MW, Genevois-Borella A, Jimonet P, Pratt J, Randle JC, Ribeill Y, Vuilhorgne M, Mignani S. Synthesis of anticonvulsive AMPA antagonists: 4-oxo-10-substituted-imidaz. Bioorg Med Chem Lett. 2001 May 7;11(9):1205-10. PubMed PMID: 11354378.

7: Nikam SS, Kornberg BE. AMPA receptor antagonists. Curr Med Chem. 2001 Feb;8(2):155-70. Review. PubMed PMID: 11172672.

8: Stutzmann JM, Bohme GA, Boireau A, Damour D, Debono MW, Genevois-Borella A, Imperato A, Jimonet P, Pratt J, Randle JC, Ribeill Y, Vuilhorgne M, Mignani S. 4,10-Dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives: highly potent and selective AMPA receptors antagonists with in vivo activity. Bioorg Med Chem Lett. 2000 May 15;10(10):1133-7. PubMed PMID: 10843235.

9: Mignani S, Bohme GA, Boireau A, Cheve M, Damour D, Debono MW, Genevois-Borella A, Imperato A, Jimonet P, Pratt J, Randle JC, Ribeill Y, Vuilhorgne M, Stutzmann JM. 8-Methylureido-4,5-dihydro-4-oxo-10H-imidazo[1,2-a]indeno[1,2-e]pyrazines: highly potent in vivo AMPA antagonists. Bioorg Med Chem Lett. 2000 Mar 20;10(6):591-6. PubMed PMID: 10741560.

10: Shirane M, Nakamura K. Group II metabotropic glutamate receptors are a common target of N-anisoyl-GABA and 1S,3R-ACPD in enhancing ACh release in the prefrontal cortex of freely moving SHRSP. Neuropharmacology. 2000 Mar 3;39(5):866-72. PubMed PMID: 10699452.

11: YM 900. YM 90K. Drugs R D. 1999 Jan;1(1):42-3. PubMed PMID: 10565984.

12: Kodama M, Yamada N, Sato K, Kitamura Y, Koyama F, Sato T, Morimoto K, Kuroda S. Effects of YM90K, a selective AMPA receptor antagonist, on amygdala-kindling and long-term hippocampal potentiation in the rat. Eur J Pharmacol. 1999 Jun 11;374(1):11-9. PubMed PMID: 10422635.

13: Shimojo M, Takasugi K, Yamamoto I, Funato H, Mochizuki H, Kohsaka S. Neuroprotective action of a novel compound--M50463--in primary cultured neurons. Brain Res. 1999 Jan 2;815(1):131-9. PubMed PMID: 9974133.

14: Arias RL, Tasse JR, Bowlby MR. Neuroprotective interaction effects of NMDA and AMPA receptor antagonists in an in vitro model of cerebral ischemia. Brain Res. 1999 Jan 23;816(2):299-308. PubMed PMID: 9878799.

15: Boireau A, Meunier M, Imperato A. Ouabain-induced increase in dopamine release from mouse striatal slices is antagonized by riluzole. J Pharm Pharmacol. 1998 Nov;50(11):1293-7. PubMed PMID: 9877317.

16: Takamatsu H, Kondo K, Ikeda Y, Umemura K. Neuroprotective effects depend on the model of focal ischemia following middle cerebral artery occlusion. Eur J Pharmacol. 1998 Dec 4;362(2-3):137-42. PubMed PMID: 9874163.

17: Li H, Matsumoto K, Watanabe H. An alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) antagonist and an N-methyl-D-aspartate (NMDA) channel blocker synergistically impair spatial memory in rats. Biol Pharm Bull. 1998 Nov;21(11):1228-30. PubMed PMID: 9853420.

18: Kawasaki-Yatsugi S, Ichiki C, Yatsugi S, Shimizu-Sasamata M, Yamaguchi T. YM90K, an AMPA receptor antagonist, protects against ischemic damage caused by permanent and transient middle cerebral artery occlusion in rats. Naunyn Schmiedebergs Arch Pharmacol. 1998 Nov;358(5):586-91. PubMed PMID: 9840429.

19: Kawasaki-Yatsugi S, Shimizu-Sasamata M, Yatsugi S, Yamaguchi T. Delayed treatment with YM90K, an AMPA receptor antagonist, protects against ischaemic damage after middle cerebral artery occlusion in rats. J Pharm Pharmacol. 1998 Aug;50(8):891-8. PubMed PMID: 9751454.

20: Kohara A, Okada M, Tsutsumi R, Ohno K, Takahashi M, Shimizu-Sasamata M, Shishikura J, Inami H, Sakamoto S, Yamaguchi T. In-vitro characterization of YM872, a selective, potent and highly water-soluble alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist. J Pharm Pharmacol. 1998 Jul;50(7):795-801. PubMed PMID: 9720630.